Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged,
causing a global pandemic called COVID-19. Currently, there is no definitive treatment for …
causing a global pandemic called COVID-19. Currently, there is no definitive treatment for …
Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab
A Caballero, LM Filgueira, J Betancourt… - Clinical & …, 2020 - Wiley Online Library
Objectives COVID‐19 can lead to a hyperinflammatory state. CD6 is a glycoprotein
expressed on mature T lymphocytes which is a crucial regulator of the T‐cell activation …
expressed on mature T lymphocytes which is a crucial regulator of the T‐cell activation …
DFT and docking studies of designed conjugates of noscapines & repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2
First case of the present epidemic, coronavirus disease (COVID-19) is reported in the
Wuhan, a city of the China and all the countries throughout the world are being affected …
Wuhan, a city of the China and all the countries throughout the world are being affected …
Druggable targets and therapeutic development for COVID-19
Coronavirus disease (COVID-19), which is caused by SARS-CoV-2, is the biggest challenge
to the global public health and economy in recent years. Until now, only limited therapeutic …
to the global public health and economy in recent years. Until now, only limited therapeutic …
Inhibitory potential of phytochemicals on interleukin-6-mediated T-cell reduction in COVID-19 patients: A computational approach
Background: A recent COVID-19 pandemic has resulted in a large death toll rate globally
and even no cure or vaccine has been successfully employed to combat this disease …
and even no cure or vaccine has been successfully employed to combat this disease …
[HTML][HTML] Therapeutic approaches in modulating the inflammatory and immunological response in patients with sepsis, acute respiratory distress syndrome, and …
Y Mehta, SB Dixit, K Zirpe, R Sud, PB Gopal, PA Koul… - Cureus, 2021 - ncbi.nlm.nih.gov
Immunomodulation has long been an adjunct approach in treating critically ill patients with
sepsis, acute respiratory distress syndrome (ARDS), and acute pancreatitis (AP) …
sepsis, acute respiratory distress syndrome (ARDS), and acute pancreatitis (AP) …
Computational chemistry to repurposing drugs for the control of COVID-19
M Hassanzadeganroudsari, AH Ahmadi, N Rashidi… - Biologics, 2021 - mdpi.com
Thus far, in 2021, 219 countries with over 175 million people have been infected by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a positive sense …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a positive sense …
Monoclonal antibodies as potential COVID-19 therapeutic agents
J Plichta, P Kuna, M Panek - COVID, 2022 - mdpi.com
The COVID-19 pandemic continues to cause tremendous loss of life and put massive strain
on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral …
on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral …
Clinical and regulatory challenges and opportunities for monoclonal antibodies in low-and middle-income countries: Lessons from COVID-19 and beyond
L Gieber, V Muturi-Kioi, S Malhotra, A Sitlani - Pharmaceutical Medicine, 2023 - Springer
Monoclonal antibodies are an effective and growing class of pharmaceuticals for the
treatment and prevention of a broad range of non-communicable and infectious diseases; …
treatment and prevention of a broad range of non-communicable and infectious diseases; …